Eli Lilly and Company - Change In Working Capital

Eli Lilly and Company's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Change-In-Working-Capital" stands at -2.22 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value since 12/31/2023.

Eli Lilly and Company's third quarter result of 5.63 Billion USD for the item "Change In Working Capital" represents an increase of 348.67 percent compared to it's second quarter result.

Also, Eli Lilly and Company's third quarter result of 5.63 Billion USD for the item "Change In Working Capital" represents an increase of 57,519.39 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Eli Lilly and Company's third quarter result of -2.22 Billion USD for the item "Change In Working Capital" represents an increase of 71.70 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 4.11 Billion United States Dollars compared to the value the year prior.
The 1 year change is 4.11 Billion United States Dollars.
The 3 year change is -2.57 Billion United States Dollars.
The 5 year change is -2.07 Billion United States Dollars.
The 10 year change is -1.77 Billion United States Dollars.

The Serie's long term average value is -1.00 Billion United States Dollars. It's latest available value, on 09/30/2025, is -1.22 Billion United States Dollars lower, compared to it's long term average value.
The Serie's change in United States Dollars from it's minimum value, on 06/30/2025, to it's latest available value, on 09/30/2025, is +5.64 Billion.
The Serie's change in United States Dollars from it's maximum value, on 12/31/2017, to it's latest available value, on 09/30/2025, is -5.43 Billion.